KRAS and neoplasm: demonstrated that the upregulation of IL1RN-201/203 and anakinra treatment in KRAS-mutant intrahepatic cholangiocarcinoma mice significantly enhanced the anti-tumor immune response by altering neutrophil recruitment and phenotype.